These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 24439564)

  • 1. The challenge of the 'C' in CML.
    Mauro MJ
    Leuk Res; 2014 Mar; 38(3):286. PubMed ID: 24439564
    [No Abstract]   [Full Text] [Related]  

  • 2. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors.
    Efficace F; Rosti G; Cottone F; Breccia M; Castagnetti F; Iurlo A; Mandelli F; Baccarani M
    Leuk Res; 2014 Mar; 38(3):294-8. PubMed ID: 23906625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A limited but necessary indication of stem cell transplantation for chronic myelogeneous leukemia in the era of tyrosine kinase inhibitors.
    Imataki O
    Transplantation; 2014 Jan; 97(1):e4-5. PubMed ID: 24374768
    [No Abstract]   [Full Text] [Related]  

  • 4. Patient empowerment in the management of chronic myeloid leukemia.
    Coleman M
    Clin J Oncol Nurs; 2014 Apr; 18(2):E12-8. PubMed ID: 24675265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Another piece of the puzzle--optimal TKI selection before treatment discontinuation in CML.
    Wolf D
    Eur J Haematol; 2015 Mar; 94(3):189-90. PubMed ID: 25712068
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
    Murphy M; Close J; Lottenberg R; Rajasekhar A
    Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
    [No Abstract]   [Full Text] [Related]  

  • 7. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 8. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations.
    Bonifacio M; Binotto G; Calistri E; Maino E; Tiribelli M;
    Ann Hematol; 2014 Jan; 93(1):163-4. PubMed ID: 24292539
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic myeloid leukemia with pregnancy: Successful management of pregnancy and delivery with hydroxyurea and imatinib continued till delivery.
    Yadav U; Solanki SL; Yadav R
    J Cancer Res Ther; 2013; 9(3):484-6. PubMed ID: 24125987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chakalaka-induced vasodilatation in patients with chronic myeloid leukaemia on tyrosine kinase inhibitors.
    Coetzee MJ; Louw VJ; Gartrell K; Viljoen CD
    S Afr Med J; 2009 Dec; 99(12):870-1. PubMed ID: 20459996
    [No Abstract]   [Full Text] [Related]  

  • 11. Part I: Milestones in personalised medicine--imatinib.
    Gambacorti-Passerini C
    Lancet Oncol; 2008 Jun; 9(6):600. PubMed ID: 18510992
    [No Abstract]   [Full Text] [Related]  

  • 12. Treating chronic myeloid leukemia: improving management through understanding of the patient experience.
    Simoneau CA
    Clin J Oncol Nurs; 2013 Feb; 17(1):E13-20. PubMed ID: 23372106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
    Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
    Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronic myeloid leukemia treatment and human immunodeficiency virus infection].
    Campillo-Recio D; Perez-Rodriguez L; Yebra E; Cervero-Jimenez M
    Rev Clin Esp (Barc); 2014 May; 214(4):231-2. PubMed ID: 24564991
    [No Abstract]   [Full Text] [Related]  

  • 15. Leukocytosis: the mysteries within.
    Munoz J; Guo Y
    Am J Hematol; 2012 Feb; 87(2):197. PubMed ID: 21815181
    [No Abstract]   [Full Text] [Related]  

  • 16. TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model.
    Ulmer A; Tabea Tauer J; Glauche I; Jung R; Suttorp M
    Klin Padiatr; 2013 May; 225(3):120-6. PubMed ID: 23716272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myelogenous leukemia therapy beyond imatinib.
    Deininger M
    Clin Adv Hematol Oncol; 2010 Mar; 8(3):178-80. PubMed ID: 20400933
    [No Abstract]   [Full Text] [Related]  

  • 19. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
    Efficace F; Breccia M; Saussele S; Kossak-Roth U; Cardoni A; Caocci G; Chie W; Naeem A; Nicolatou-Galitis O; Cocks K; Vignetti M; Baccarani M; Mandelli F; Sprangers M
    Ann Hematol; 2012 Sep; 91(9):1371-81. PubMed ID: 22543826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate for the treatment of chronic myeloid leukemia.
    Soverini S; Martinelli G; Iacobucci I; Baccarani M
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):853-64. PubMed ID: 18533795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.